Meet
Laura DiAngelo

Laura DiAngelo researches federal healthcare policy developments and writes timely, relevant analysis for life sciences clients.

She provides insights showing how legislation and administrative policy impact short- and long-term business goals. With experience in regulatory policy and processes and federal payment pathways, she provides in-depth policy analysis for clients to help them anticipate trends and major issues impacting life sciences manufacturers and stakeholders.

Prior to joining Avalere, Laura was with Deloitte’s Center for Health Solutions, where she conducted research and outreach in support of the Center’s publications and wrote the weekly healthcare content newsletter.

Laura has an MPH in health policy from the George Washington University and a BA from Binghamton State University of New York.

Authored Content


Beginning in January 2019, Medicare Advantage (MA) plans will have the flexibility to use step-therapy techniques for Part B drugs, according to a CMS memo released on August 7.

Earlier this week, the Food & Drug Administration (FDA) released a Part 15 public hearing announcement and request for comment on how the FDA can facilitate greater availability while balancing competition and innovation for all biologics.

On June 27, CMS notified Massachusetts of a partial approval of the MassHealth program’s proposed 1115 waiver request.

In its 2018 Report, the Medicare Trustees issued a Medicare funding warning, citing concerns over the program's near-term financial health and spending impact on the federal budget.

The House and Senate are advancing legislative packages aimed at mitigating the crisis.

In response to the concern that overprescribing is a driver of the opioid crisis, payers are limiting opioid fills as one solution.